Scarica l'app Stockscreener
1.80
0.00%
0.01
Gri Bio Inc Borsa (GRI) Ultime notizie
Price to earnings forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
Price to sales forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to revenue forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
Enterprise value to EBIT forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
Price to earnings forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to EBIT forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to EBITDA forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Bio, Inc. Actuals & Estimates (NASDAQ:GRI) - TradingView
GRI Forecast — Price Target — Prediction for 2027 - TradingView
GRI Bio Inc. (GRI) Rallies 3.8% as Momentum Builds Above Key SupportBollinger Expansion - dars.gov.et
GRI Bio Inc (GRI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GRI Bio Inc (GRI) Institutional Confidence - TradingKey
GRI Bio Inc (GRI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GRI Bio Secures FDA Orphan Drug Status for IPF - TipRanks
FDA grants Orphan Drug Designation to GRI Bio (NASDAQ: GRI) therapy GRI-0621 in IPF - Stock Titan
GRI Bio receives orphan drug status for IPF treatment - Investing.com
GRI Bio receives FDA orphan drug designation for IPF treatment - grafa.com
GRI Bio receives orphan drug status for IPF treatment By Investing.com - Investing.com Canada
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - GlobeNewswire
GRI Bio Inc (GRI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
FDA gives GRI Bio a rare-disease boost for lung scarring drug - Stock Titan
GRI Bio Inc (GRI) Valuation: PE, PB & Fair Value Analysis - TradingKey
GRI Bio Inc (GRI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GRI Bio Inc (GRI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GRI Bio Inc (GRI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GRI Bio Inc (GRI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GRIGRI Bio Inc Forecast, Target Price - Finviz
GRI Q1 2026 Earnings: EPS Misses Estimates by 76% Amid Revenue AbsenceEarnings Per Share - lwvtexas.org
GRI Bio Inc. (GRI) Slips Over 5% as Stock Tests Key Support Near $1.90Median Line - newsline.com
GRI Q1 2026 Earnings: EPS Miss by 76% as Pre-Clinical Biotech Continues to Report No RevenueWeak Earnings Momentum - newsline.com
GRI Q1 2026 Earnings: Wider-than-Expected Loss as EPS Misses EstimatesLong-Term Guidance - newsline.com
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know - Benzinga
GRI Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid Stepped-Up R&D SpendingROIC Trend Report - newsline.com
GRI Q1 2026 Earnings: Wider-than-Expected Loss as EPS Misses Estimates by 76%Dividend Increase Stocks - newsline.com
GRI Bio Inc. (GRI) Struggles Near Support Amid Mixed Technical SignalsVolume Gap - The Legal Advocate
GRI Bio Inc. (GRI) Posts Modest Gains as Stock Holds Above Key SupportWyckoff Spring - The Legal Advocate
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Company Faces HeadwindsEPS Consistency Score - The Legal Advocate
GRI Bio Inc. (GRI) Slides 7% as Shares Test Key Support at $1.96Relative Volume - Newser
GRI Bio (GRI) Q1 2026 Results Miss Estimates — EPS $-1.61 vs $-0.91Positive Surprise Momentum - Newser
GRI Bio CEO to discuss innovative immune therapies at healthcare showcase May 20 - Pluang
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase - GlobeNewswire
Number of shareholders of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Bio (GRI) Falls -5.56% — Watching $1.94 Support 2026-05-15Sector Rotation - Newser
GRI Bio Reports Positive Phase 2a Results for GRI-0621 in IPF and Advances Immune-Modulating Pipeline with Strong Q1 2026 Financials - Minichart
GRI Bio Highlights Promising Phase 2a IPF Data, Outlook - TipRanks
GRI Bio reports phase 2a data for IPF drug candidate GRI-0621 - Investing.com
GRI Bio Q1 net loss narrows on lower R&D expenses - TradingView
IPF Phase 2a results and cash runway update for GRI Bio (NASDAQ: GRI) - Stock Titan
GRI Bio Reports First Quarter 2026 Financial Results, New - GlobeNewswire
H.C. Wainwright Maintains GRI Bio(GRI.US) With Buy Rating, Maintains Target Price $10 - Moomoo
GRI BIO ($GRI) Releases Q1 2026 Earnings - Moomoo
GRI Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GRI Bio (GRI) Schedule 13G/A: 90,475 shares represent 5.9% stake - Stock Titan
GRI Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
GRI Bio (NASDAQ: GRI) Q1 loss narrows as cash runway extends into 2027 - Stock Titan
Is GRI Bio (GRI) stock hiding in plain sight? (+1.78%) 2026-05-11Low Volatility Stocks - Newser
2.26%
2.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):